not differ between groups (Table 2 ). The rate of DU was highest (20%) and the rate of BOO was lowest (6%) in the moderate POP group, with 23% of women in this group reporting incomplete emptying, 14% reporting hesitancy, and 8% reporting splinting to urinate (Table 1) . CONCLUSION: Detrusor contractility was not associated with the severity of POP. Worsening prolapse is associated with obstructive symptoms even in the absence of urodynamic evidence of BOO. Underactive bladder may contribute to symptoms in women with moderate anterior vaginal wall prolapse.
, number of concomitant procedures and patient age stratified by decade. Prescription data were converted into oral morphine equivalents (OME's) and medication refills were assessed. Patients with a history of opioid use within 90 days of surgery were considered preoperative opioid users. X 2 or Fisher's exact analysis were utilized for categorical variables and student's t-test for continuous. Cochran-Armitage trend tests were used to assess trends. Pearson's correlation coefficient assessed correlation of pain scores to prescribed OME and refills. RESULTS: A total of 1943 patients underwent surgical treatment of POP; of these, 113 (5.8%) were preoperative opioid users. Preoperative opioid users were younger (55.5 yrs vs 59.5 yrs, p¼0.01), of slightly higher BMI (BMI 29.2 vs 28.3, p¼0.04) , and less likely to be white (90.3% vs 95.9%, p¼0.01) than opioid naïve patients. Smoking rates, surgical approach, number of concomitant procedures performed and length of stay did not differ between groups. Higher mean pain scores (3.5 vs 2.5), OME's prescribed (324.4 vs 285.1) and refill rates (16.8% vs 6.4%) were seen in preoperative opioid users. While in the opioid naïve cohort, both surgical approach and the number of concomitant procedures influenced pain scores, this was not seen in the preoperative opioid using group (p¼0.95 and p¼0.63). With decreasing patient age by decade, both groups demonstrated a significant increase in pain scores and opioid refill rates regardless of surgical approach (p<0.02). However, a Non-Oral Posters decrease in OME's prescribed with increasing age by decade was only seen in the opioid naïve group. Pain scores were directly correlated to the amount of opioid prescribed in both groups (p>0.01); the absence of a statistically significant age-related trend in OME's prescribed for pre-operative opioid users (541 to 226 from youngest to oldest, p¼0.056) is likely due to a lack of power in this smaller group. CONCLUSION: Among patients undergoing POP surgery, preoperative opioid users had higher mean pain scores, were prescribed more OME's and had higher opioid refill rates. They were also, younger, of higher BMI and less likely to be white. In both preoperative opioid using and opioid naïve groups, younger patients had higher pain scores and opioid refill rates.
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Douglas A. Leach: Nothing to disclose; Elizabeth Habermann: Nothing to disclose; Amy E. Glasgow: Nothing to disclose; John A. Occhino: Nothing to disclose. OBJECTIVES: Women with refractory urgency urinary incontinence (UUI) can be treated with onabotulinumtoxinA (BTX) or sacral neuromodulation (SNM). The goal of this study was to compare the impact of these treatments on bowel and sexual function. MATERIALS AND METHODS: This was a planned supplemental analysis of a randomized trial in women with refractory UUI treated with BTX (n¼190) or SNM (n¼174). Bowel and sexual symptoms were measured at baseline, 6, 12, and 24 months. Bowel symptoms were measured using the St Mark's (Vaizey) Fecal Incontinence severity scale. Sexual symptoms were measured using the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire-12 (PISQ-12) and the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). The PISQ-IR allows calculation of 6 subscores for sexually active women (SA-AO: Arousal, Orgasm; SA-PR: Partner Related; SA-CS: Condition Specific; SA-GQR: Global Quality Rating; SA-CI: Condition Impact; SA-D: Desire) and 4 subscores for those not sexually active (NSA-PR; NSA-CS; NSA-GQR; and NSA-CI). Primary outcome was change in Vaizey and PISQ-12 scores between baseline and 6 months. Secondary outcomes were change in PISQ-IR scores between baseline and 6 months and change in Vaizey, PISQ-12 and PISQ-IR scores between baseline and 12 and 24 months. Intent to treat analysis was performed using repeated measures mixed model to estimate change in all parameters from baseline while adjusting for the baseline score. A subgroup analysis of women with clinically significant bowel symptoms was conducted based on baseline Vaizey score of 12.
RESULTS: There were no differences between BTX and SNM groups in baseline Vaizey (7.6+5.3 v 6.6+4.9, p¼0.07), p¼0.55) , or PISQ-IR subscores. 39% in BTX and 45% in SNM group were sexually active at baseline (p¼0.25). There was no difference between women treated with BTX and SNM at 6 months in improvement in Vaizey score (-1.9, 95% CI -2.6 to -1.2 v -0.9, 95% CI -1.7 to -0.2, p¼0.07) or PISQ-12 score (2.2, 95% CI 0.7 to 3.7 v 2.2, 95% CI 0.7 to 3.7, p¼0.99). There was no difference in improvement between groups in the PISQ-IR subscores at 6 months, or the Vaizey, PISQ-12, and PISQ-IR subscores at 12 and 24 months. In a subgroup (BTX¼33 and SNM¼22) with baseline Vaizey score 12, there was a clinically important improvement in bowel symptoms in both groups from baseline to 6 months with no difference in improvement between the BTX and SNM groups (-5.1, 95% CI -7.3 to -2.8 v -5.6, 95% CI -8.5 to -2.6, p¼0.8). CONCLUSION: There were no differences in improvement of bowel and sexual symptoms in women with UUI treated with BTX or SNM. Women with clinically significant bowel symptoms at baseline had improvement in symptoms although there was no difference between the treatments. Our findings may not pertain to a fecal incontinence or sexual dysfunction treatment-seeking group. OBJECTIVES: For some patients with both rectal and vaginal prolapse, a perineal approach to combined prolapse repair with rectal fixation would improve prolapse outcomes and be less morbid than an abdominal approach. Utilization of the sacrospinous ligaments and uterosacral ligaments for vaginal apical suspension has been well described with good surgical outcomes and improvement in vaginal prolapse symptoms. Here, we describe using the sacrospinous ligament and uterosacral ligament as a point of fixation for rectal prolapse and vaginal prolapse via a transvaginal approach. MATERIALS AND METHODS: Patients with full thickness rectal prolapse and symptomatic pelvic organ prolapse underwent concurrent rectopexy and vaginal vault suspension with the following steps: 1. Exposure of the sacrospinous ligaments through an extra-peritoneal approach or exposure of the uterosacral ligaments through an intraperitoneal approach. 2. Placement of two or three absorbable sutures through the bilateral ligaments. 3. Placement of an EEA sizer in the rectum and fixation of the sutures through the proximal and distal anterior rectal wall. 4. Suspension of the vagina and rectum by bringing the sutures through the vaginal cuff. 5. Performance of a rectal exam to ensure minimal tension on the rectum.

